Sana's Gene Therapy Platform
GPTKB entity
Properties (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy platform
|
| gptkbp:addressed |
genetic disorders
unmet medical needs |
| gptkbp:aimsTo |
patient outcomes
genetic material treatment options treat rare diseases |
| gptkbp:associated_with |
gptkb:Sana_Biotechnology
|
| gptkbp:basedOn |
gptkb:Seattle,_Washington
|
| gptkbp:collaborates_with |
biopharmaceutical companies
clinical research projects |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:develops |
gene therapies
|
| gptkbp:developsStrategiesFor |
oncology
|
| gptkbp:established |
2020
|
| gptkbp:explores |
combination therapies
new delivery methods |
| gptkbp:has_a |
therapeutic candidates
|
| gptkbp:has_a_focus_on |
genetic diseases
therapeutic efficacy long-term outcomes cell and gene therapies improving delivery efficiency |
| gptkbp:has_partnerships_with |
research institutions
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sana's Gene Therapy Platform
|
| gptkbp:impact |
patient quality of life
research collaborations patient access to therapies therapeutic delivery systems clinical trial designs |
| gptkbp:is_a_platform_for |
chronic diseases
|
| gptkbp:is_aimed_at |
reduce treatment costs
transform treatment paradigms |
| gptkbp:is_committed_to |
patient safety
ethical research practices safety and efficacy transparency in research. |
| gptkbp:is_designed_to |
correct genetic mutations
|
| gptkbp:is_expected_to |
advance personalized medicine
future treatments |
| gptkbp:is_funded_by |
venture capital
|
| gptkbp:is_governed_by |
gptkb:FDA
|
| gptkbp:is_involved_in |
clinical trials
preclinical studies biomarker_discovery |
| gptkbp:is_known_for |
innovative approaches to gene editing
|
| gptkbp:is_part_of |
the healthcare ecosystem
growing field of research the biotechnology industry |
| gptkbp:is_recognized_for |
scientific innovation
|
| gptkbp:isEngagedIn |
advanced technologies
data analytics |
| gptkbp:leadership |
gene editing technologies
|
| gptkbp:number_of_teams |
scientists and researchers
|
| gptkbp:produces |
innovative therapies
|
| gptkbp:publishedBy |
research findings
|
| gptkbp:receives |
orphan_drug_designation
|
| gptkbp:targets |
muscle diseases
|
| gptkbp:uses |
CRISPR technology
|
| gptkbp:utilizes |
next-generation sequencing
viral vectors |
| gptkbp:works_with |
regulatory agencies
regenerative medicine |